Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.

Cancer Sci · 2023 · PMC9899610 · PMID 35838190

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Serum FGF23 levels were markedly upregulated after repeated doses with both the TIW and QD regimens compared with baseline levels on day 1, and showed a trend towards dose dependency.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.